Theradiag receives CE mark approval
for two new Lisa Tracker monitoring kits in theranostics

 

 

Croissy-Beaubourg, February 14 2013 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced  it has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that further expand the Lisa Tracker range.

 

With these two new additions available in all EU countries, Theradiag now offers a range of seven blood test kits providing comprehensive multi-parameter diagnosis solutions to monitor patients with autoimmune and inflammatory diseases. Rituximab is also used to treat hematological cancers.

 

Michel Finance, CEO of THERADIAG, says: “These two new monitoring kits expand our theranostic range to cancerology and show that we are on track to meet our roadmap targets. The Lisa Tracker range is a unique diagnostic tool which enables physicians to tailor treatments and optimize patient care. This new CE mark outlines our expert know-how in our lines of innovative proprietary diagnostic products and their sale in international markets”.

 

About Theradiag

Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. Theradiag recorded revenue of €6.4 million at 30 September 2012. The Company is based in Marne-la-Vallée, near Paris, and has some 50 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

 

 

Theradiag

Michel Finance

CEO

Tel: +33 (0)1 64 62 38 73

mfinance@theradiag.com

 

NewCap.

Financial communication
& Investor relations

Valentine Brouchot /

Pierre Laurent

Tel: +33 (0)1 44 71 98 52 theradiag@newcap.fr

 

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 (0)6 64 18 99 59

Christian Berg
christian@alizerp.com

Tel: +33 (0)1 42 68 86 41